Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Equity Average (2016 - 2025)

Historic Equity Average for Pharma (IGC) over the last 16 years, with Q3 2025 value amounting to $7.1 million.

  • Pharma's Equity Average fell 712.46% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 712.46%. This contributed to the annual value of $6.8 million for FY2025, which is 3859.75% down from last year.
  • Pharma's Equity Average amounted to $7.1 million in Q3 2025, which was down 712.46% from $6.2 million recorded in Q2 2025.
  • Pharma's Equity Average's 5-year high stood at $32.3 million during Q2 2021, with a 5-year trough of $6.2 million in Q2 2025.
  • In the last 5 years, Pharma's Equity Average had a median value of $14.1 million in 2023 and averaged $16.7 million.
  • In the last 5 years, Pharma's Equity Average surged by 3474.82% in 2021 and then crashed by 5072.23% in 2024.
  • Quarter analysis of 5 years shows Pharma's Equity Average stood at $30.4 million in 2021, then plummeted by 36.67% to $19.2 million in 2022, then crashed by 39.81% to $11.6 million in 2023, then tumbled by 41.1% to $6.8 million in 2024, then grew by 3.92% to $7.1 million in 2025.
  • Its Equity Average stands at $7.1 million for Q3 2025, versus $6.2 million for Q2 2025 and $6.3 million for Q1 2025.